Loading…
← CockpitCompetitor Analysis › BEAM Beam Therapeutics, Inc.Open in the cockpit ↗

Beam Therapeutics, Inc.BEAMCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.

Momentum weak 22
Mkt cap
$2.17B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$57.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 15.1%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$21.01
1D+1.7%
1W-18.6%
1M-15.7%
3M-26.0%
6M-22.5%
YTD-24.2%
1Y-4.6%
ATR %8.2%
Beta2.23
52w lowhigh45.1% off high

What Beam Therapeutics does

Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.

Has no approved product, so its income is collaboration payments and money raised from investors, not sales. Value rests on moving its first treatments, such as BEAM-101 for sickle cell disease, through clinical trials. It also has research partnerships with larger drugmakers that pay upfront and milestone fees.

Products and services

  • BEAM-101 (sickle cell disease)
  • Base editing platform pipeline (liver, immune diseases)

Customers

  • Hematologists/specialty centers (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Base editing gene therapy

What could go right

  • BEAM-101 regulatory path
  • Platform expansion into in vivo editing

What could go wrong

  • Clinical trial and manufacturing risk
  • Competitive intensity in gene editing

Moat: narrow (IP / patents, process know-how). Proprietary base-editing technology, more precise than CRISPR cutting, with broad foundational patents.

Headquarters: Cambridge, Massachusetts, US · Founded: 2017 · Employees: 511

Named competitors

Beam Therapeutics at a glance

Size Beam Therapeutics (BEAM) is a United States Health Care company (Biotechnology) with a market value of $2.17B, the 1723rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $21.01 on 18 Nov 2026.

Performance Over six months the shares fell 22.5%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 163.3% over the last twelve months (peer median +0.3%); the operating margin is -267.7% (peer median -15.4%).

Valuation It trades at 9.4× enterprise value to sales against a peer median of 9.8× (7th cheapest of 15).

Short interest Short interest is 25.2% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 92BEAM 76
Six months, rebased to 100: Beam Therapeutics against the median of its 20 peers (local-currency closes).

Beam Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$147M$140M$63.5M$378M$60.9M
Revenue growth—+120%-83%+520%—
Gross profit$125M$117M$41.6M$358M$38.3M
EBITDA-$370M-$361M-$394M-$156M-$316M
Net income-$107M-$80.0M-$377M-$133M-$289M
Free cash flow-$398M-$360M-$356M-$183M-$26.4M
Capital expenditure$9.59M$14.9M$8.95M$33.7M$49.0M
Total debt$244M$154M$161M$173M$182M

Quarterly statements and history in the cockpit →

Beam Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%CLDXZEALPVLAPHVS300676ALMR302440RCUS300255MRVI300142REPLBEAM6-month return →1-month return →
Up and to the right = strong over both horizons. Beam Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×5,000×10,000×CLDXZEAL300676ALMR302440RCUS300142BCRXBEAMRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beam Therapeutics is the large dot.

Beam Therapeutics competitors and peer comparison

Head to head with its named competitors (BEAM vs NTLA vs CRSP vs EDIT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Beam Therapeutics BEAM$2.17B-22%+163%-268%9.4×n/a
Intellia Therapeutics NTLA$1.37B-20%-8%-821%21.3×n/a
CRISPR Therapeutics CRSP$3.90B-17%-34%-2,059%95.6×n/a
Editas Medicine EDITn/a-32%n/an/an/an/a
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%

How Beam Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beam Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureBEAMPeer medianRank in peer set
1-month return-15.7%-4.9%6th lowest of 21
6-month return-22.5%-10.8%6th lowest of 20
Distance from 52-week high-45.1%-34.1%7th lowest of 21
Revenue growth (TTM)+163.3%+0.3%3rd highest of 17
Operating margin-267.7%-15.4%3rd lowest of 15
EV / Sales9.4×9.8×7th cheapest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a

Questions

Who are Beam Therapeutics's main competitors?
Named competitors: Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX). The cockpit's measured peer set (industry) also includes Celldex Therapeutics (CLDX), Zealand Pharma A/S (ZEAL.CO), Palvella Therapeutics (PVLA), Pharvaris (PHVS), BGI Genomics (300676.SZ), Alamar Biosciences (ALMR).
Is Beam Therapeutics expensive compared with its peers?
On ev / sales it trades at 9.4× against a peer median of 9.8×, 7th cheapest of 15 in its peer set.
How has Beam Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -22.5% against -10.8% for the median peer; over one year -4.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.